Global Market Research Reports

  Overview and Scope The ovarian cancer drugs refer to cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in the ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer. The ovarian cancer drugs include Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide) and others.   Sizing and Forecast The ovarian cancer drugs market size has grown rapidly in recent years. It will grow from $4.48 billion in 2023 to $5.16 billion in 2024 at a compound annual growth rate (CAGR) of 15.0%.   The   growth in the historic period can be attributed to rising incidences of ovarian cancer, a rise of new medications and therapies, an increase in government initiatives for ovarian cancer treatment and increased healthcare expenditure. ...